The EU's highest court ruled that EU national courts don't need scientific proof to consider a vaccine as defect.

A shareholder campaign demanding change at Mylan has come up short.

A federal jury has found that Teva must pay GlaxoSmithKline $235 million in a carve-out patent case over heart drug Coreg.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

Seqirus said it has achieved an industry first by producing a cell-based influenza vaccine on a commercial scale using a virus grown in cells.

Biopharma and its investors are breathing a sigh of relief on reports of the White House's drug pricing plans.

It’s a two-fer for McCann Health. The agency won Cannes Lions Health network advertising agency of the year for the second year in a row.

Shire nabbed FDA approval Wednesday for its new long-acting ADHD drug Mydayis, and it's targeting $500 million in sales by 2020.